Aspen Aerogels (NYSE:ASPN) Issues Q3 2026 Earnings Guidance

Aspen Aerogels (NYSE:ASPN) issued an update on its third quarter 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of -0.110–0.070 for the period, compared to the consensus EPS estimate of -0.130. The company issued revenue guidance of $65.0 million-$80.0 million, compared to the consensus revenue estimate of $56.6 million.

Aspen Aerogels Stock Down 11.8%

ASPN stock traded down $0.81 during midday trading on Friday, hitting $6.08. 737,614 shares of the company’s stock were exchanged, compared to its average volume of 1,594,639. The stock has a market capitalization of $503.50 million, a price-to-earnings ratio of -4.46 and a beta of 2.99. Aspen Aerogels has a 12-month low of $2.30 and a 12-month high of $9.35. The company has a current ratio of 2.89, a quick ratio of 2.54 and a debt-to-equity ratio of 0.32. The firm has a 50 day moving average price of $5.51 and a 200-day moving average price of $4.41.

Aspen Aerogels (NYSE:ASPN) last released its quarterly earnings data on Thursday, May 7th. The construction company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.01). The company had revenue of $37.88 million for the quarter, compared to the consensus estimate of $36.58 million. Aspen Aerogels had a negative return on equity of 22.16% and a negative net margin of 48.64%.The business’s revenue was down 51.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.06) earnings per share. On average, analysts anticipate that Aspen Aerogels will post -0.8 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ASPN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aspen Aerogels in a research report on Wednesday, June 24th. Roth Capital reiterated a “buy” rating on shares of Aspen Aerogels in a report on Friday. Barclays upped their target price on shares of Aspen Aerogels from $3.00 to $4.00 and gave the stock an “underweight” rating in a research report on Monday, May 11th. Wall Street Zen raised Aspen Aerogels from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, B. Riley Financial reissued a “buy” rating on shares of Aspen Aerogels in a report on Friday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $5.19.

Trending Headlines about Aspen Aerogels

Here are the key news stories impacting Aspen Aerogels this week:

• Positive Sentiment: Revenue and thermal-barrier demand exceeded expectations. Second-quarter revenue reached $49.85 million, above the $42.42 million analyst consensus. Thermal Barrier revenue was $29.5 million, an 81% increase from the prior quarter. Aspen Aerogels Second Quarter 2026 Financial Results
• Positive Sentiment: Third-quarter guidance was ahead of consensus. Aspen expects revenue of $65 million to $80 million and adjusted EBITDA of $7 million to $15 million, while its EPS-loss forecast of $0.11 to $0.07 is better than the $0.13 consensus estimate. Aspen Aerogels Reports Q2 Loss
• Positive Sentiment: Business development remained encouraging. The company raised its 2026 European Thermal Barrier revenue outlook to $20 million-$30 million and received a PyroThin award from Jaguar Land Rover covering two next-generation vehicle architectures. Aspen Aerogels 2026 Q2 Earnings Presentation
• Neutral Sentiment: Russell 1000 inclusion could improve visibility. Coverage highlighted Aspen Aerogels’ Russell 1000-related news, which may broaden institutional awareness and passive-fund exposure, although the direct financial impact is uncertain. Why Aspen Aerogels Is Making Russell 1000 News
• Negative Sentiment: Profitability remains the key weakness. Aspen posted a $0.22-per-share loss, only slightly better than estimates, compared with a $0.04 loss a year earlier. The company continues to report negative margins and return on equity, which may be outweighing the revenue and guidance beats. Aspen Aerogels Q2 2026 Earnings Call Transcript

Hedge Funds Weigh In On Aspen Aerogels

Several institutional investors have recently made changes to their positions in the stock. WINTON GROUP Ltd acquired a new position in Aspen Aerogels during the fourth quarter worth about $40,000. StoneX Group Inc. purchased a new stake in shares of Aspen Aerogels during the fourth quarter valued at $41,000. Acadian Asset Management LLC acquired a new stake in Aspen Aerogels during the 1st quarter worth about $43,000. Tower Research Capital LLC TRC grew its position in Aspen Aerogels by 184.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,235 shares of the construction company’s stock worth $43,000 after purchasing an additional 4,693 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in Aspen Aerogels in the 4th quarter worth about $58,000. 97.64% of the stock is owned by institutional investors.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc, headquartered in Northborough, Massachusetts, develops and manufactures high-performance aerogel insulation materials and custom engineered solutions. Founded in 2001 as a spin-out from Department of Energy research, the company pursued an initial public offering on the NYSE in 2014 under the ticker ASPN. Aspen Aerogels combines proprietary aerogel formulations with advanced manufacturing processes to deliver products known for their low thermal conductivity, lightweight construction and robust mechanical properties.

The company’s product portfolio spans blanket insulation, boards, and custom shapes built around several proprietary brands, including Pyrogel, Cryogel and Spaceloft.